Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest Simon EckermannMichael CooryAdrew R. Willan Leading Article 11 October 2012 Pages: 87 - 96
A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice Afschin Gandjour Practical Application 11 October 2012 Pages: 97 - 105
Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration Paul MitchellLieven AnnemansSimu Thomas Review Article 11 October 2012 Pages: 107 - 131
Febuxostat for the Management of Hyperuricaemia in Patients with Gout Matt StevensonAbdullah Pandor Review Article 11 October 2012 Pages: 133 - 140
A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada Mark OremusS. Carolina Aguilar Review Article 11 October 2012 Pages: 141 - 156
Impact of Treatment Success on Health Service Use and Cost in Depression Sarah ByfordBarbara BarrettAlan Wade Original Research Article 11 October 2012 Pages: 157 - 170
Erratum to: Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Chim LKelly PJSalkeld G Erratum 11 October 2012 Pages: 171 - 172